Merck Sharp & Dohme 8-K Merck Announces Strong Financial Results for the Second Quarter 2006

Exhibit 99.2

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
SECOND QUARTER
2006

OTHER (INCOME)/EXPENSE, NET (millions of dollars)

	2Q `06			2Q `05			YTD 2006			YTD 2005
INTEREST INCOME	$	(187.9	)	$	(98.7	)	$	(369.6	)	$	(192.5	)
INTEREST EXPENSE		91.9			93.1			190.1			177.6
EXCHANGE (GAINS)/LOSSES		7.4			(8.4	)		7.0			(9.1	)
MINORITY INTERESTS		30.0			30.3			59.9			60.7
Other, net		(11.5	)		(2.3	)		(58.1	)		3.9
TOTAL	$	(70.1	)	$	14.0		$	(170.7	)	$	40.6

JOINT VENTURE SALES DETAIL (millions of dollars)

All sales reported here are end-market JV sales, presented on a “NET” basis.

Merial	2Q `06		2Q `05		YTD 2006		YTD 2005
IVOMEC, HEARTGARD, other avermectins	$	121.0	$	109.6	$	250.5	$	226.3
FRONTLINE		254.0		212.4		515.5		414.3
Biologicals		152.6		130.6		292.1		251.1
Other Animal Health		58.8		59.7		114.0		115.3
TOTAL MERIAL SALES	$	586.4	$	512.3	$	1,172.1	$	1,007.0

Sanofi Pasteur-MSD	2Q `06		2Q `05		YTD 2006		YTD 2005
HEPATITIS VACCINES	$	17.4	$	23.0	$	36.5	$	44.9
VIRAL VACCINES		23.0		21.8		44.7		38.6
Other Vaccines		136.7		151.3		268.6		282.4
TOTAL SANOFI-MSD SALES	$	177.1	$	196.1	$	349.8	$	365.9

Merck / Schering-Plough Collaboration	2Q `06		2Q `05		YTD 2006		YTD 2005
VYTORIN (Worldwide)	$	497.4	$	192.6	$	875.8	$	372.0
ZETIA (Worldwide)		476.0		314.3		890.8		646.0
TOTAL	$	973.4	$	506.9	$	1,766.6	$	1,018.0

Exhibit 99.2

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
SECOND QUARTER
2006

NET PRODUCT SALES DETAIL (millions of dollars)

	2Q `06 vs. 2Q `05
	TOTAL			TOTAL		U.S.			U.S.		Foreign			Foreign
PRODUCT	% CHG			$		% CHG			$		% CHG			$
COZAAR / HYZAAR		—			784		4	%		271		-2	%		513
FOSAMAX		-4	%		821		8	%		516		-19	%		305
SINGULAIR		30	%		950		39	%		679		12	%		270
ZOCOR		-14	%		990		-9	%		742		-27	%		247
Other Reported Products:
AGGRASTAT		—			23		N/A			—		—			23
ARCOXIA		32	%		66		N/A			—		32	%		66
CANCIDAS		-12	%		124		-37	%		47		18	%		77
COSOPT / TRUSOPT		14	%		175		30	%		77		4	%		98
CRIXIVAN / STOCRIN		-16	%		74		-52	%		5		-12	%		69
EMEND		63	%		32		49	%		25		*			7
INVANZ		52	%		34		48	%		21		60	%		13
MAXALT		15	%		97		21	%		64		7	%		33
PRIMAXIN		-5	%		172		-4	%		49		-6	%		123
PROPECIA		23	%		85		19	%		37		27	%		47
PROSCAR		-3	%		183		-5	%		89		-1	%		94
TIMOPTIC / TIMOPTIC XE		-10	%		33		-19	%		2		-9	%		31
VASOTEC / VASERETIC		-14	%		140		N/A			—		-14	%		140
HEPATITIS VACCINES		28	%		59		45	%		49		-16	%		11
VIRAL VACCINES(1)		55	%		223		56	%		204		45	%		19
OTHER VACCINES		17	%		67		44	%		53		-32	%		14

*	100% or over
N/A	— Not Applicable
(1)	Includes new vaccine sales: Gardasil $10m, RotaTeq $31m, ProQuad $41m, and Zostavax $1m.

TOTAL SALES: VOLUME, PRICE, EXCHANGE

	2Q '06		% CHG.			VOL		PX		FX
TOTAL PHARMACEUTICAL SALES	$	5,772		6	%		4		2		-1
U.S. ($ MM)		3,536		17	%		10		6		N/A
Foreign ($ MM)		2,236		-8	%		-3		-3		-2

Exhibit 99.2

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
JUNE YEAR-TO-DATE
2006

NET PRODUCT SALES DETAIL (millions of dollars)

	June YTD '06 vs. June YTD '05
	TOTAL			TOTAL		U.S.			U.S.		Foreign			Foreign
PRODUCT	% CHG			$		% CHG			$		% CHG			$
COZAAR / HYZAAR		-1	%		1,485		1	%		502		-3	%		983
FOSAMAX		-3	%		1,574		10	%		973		-19	%		602
SINGULAIR		20	%		1,751		28	%		1,256		3	%		495
ZOCOR		-9	%		2,053		1	%		1,575		-32	%		478
Other Reported Products:
AGGRASTAT		-1	%		45		N/A			—		-1	%		45
ARCOXIA		18	%		126		N/A			—		18	%		126
CANCIDAS		—			270		-12	%		125		13	%		145
COSOPT / TRUSOPT		11	%		327		23	%		134		5	%		193
CRIXIVAN / STOCRIN		-7	%		156		-40	%		12		-3	%		144
EMEND		47	%		54		30	%		41		*			13
INVANZ		49	%		62		39	%		37		66	%		25
MAXALT		17	%		190		21	%		122		12	%		68
PRIMAXIN		-7	%		342		-5	%		99		-7	%		243
PROPECIA		15	%		160		13	%		72		17	%		88
PROSCAR		2	%		371		7	%		185		-2	%		186
TIMOPTIC / TIMOPTIC XE		-8	%		63		-18	%		4		-7	%		59
VASOTEC / VASERETIC		-14	%		276		N/A			—		-14	%		276
HEPATITIS VACCINES		38	%		113		55	%		90		-4	%		23
VIRAL VACCINES(1)		39	%		385		38	%		340		40	%		45
OTHER VACCINES		10	%		123		24	%		94		-19	%		29

*	100% or over
N/A	— Not Applicable
(1)	Includes new vaccine sales: Gardasil $10m, RotaTeq $33m, ProQuad $63m and Zostavax $1m.

TOTAL SALES: VOLUME, PRICE, EXCHANGE

	YTD '06		% CHG.			VOL		PX		FX
TOTAL PHARMACEUTICAL SALES	$	11,182		3	%		3		2		-2
U.S. ($ MM)		6,783		12	%		6		6		N/A
Foreign ($ MM)		4,399		-8	%		-2		-2		-3